CLOs on the Move

Southwest Virginia Community Health Systems

www.svchs.com

 
Family Healthcare in SWVA. Medical Clinics in Bristol, Tazewell, Saltvillle, Meadowview, Virginia. Primary, Behavioral, Pediatric, Optometry, Dental
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

ODONA/LTC

ODONA/LTC is a Shaker Hts, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Osseon Therapeutics

Osseon Therapeutics is a Santa Rosa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Walnut Hills Retirement Cmmty

Walnut Hills Retirement Cmmty is a Walnut Creek, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.

HedgePath Pharmaceuticals

HedgePath Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer. The Company may also explore acquiring or licensing innovative therapeutics addressing unmet needs and orphan indications beyond cancer. We are focused on the development of therapies for more than one type of cancer, with initial emphasis in the U.S. market, based upon repurposing the currently marketed antifungal drug itraconazole for new indications in oncology.